tbuckley/cabot-search huggingface dataset:
A 3D Bioprinted In Vitro Model of Pulmonary Artery Atresia to Evaluate Endothelial Cell Response to Microenvironment
Authors: Martin L. Tomov, Lilanni Perez, Liqun Ning, Huang Chen, Bowen Jing, Andrew Mingee, Sahar Ibrahim, Andrea S. Theus, Gabriella Kabboul, Katherine Do, Sai Raviteja Bhamidipati, Jordan Fischbach, Kevin McCoy, Byron A. Zambrano, Jianyi Zhang, Reza Avazmohammadi, Athanasios Mantalaris, Brooks D. Lindsey, David Frakes, Lakshmi Prasad Dasi, Vahid Serpooshan, Holly Bauser‐Heaton
Journal: Advanced Healthcare Materials (2021)

Vascular atresia are often treated via transcatheter recanalization or surgical vascular anastomosis due to congenital malformations or coronary occlusions. The cellular response to vascular anastomosis or recanalization is, however, largely unknown and current techniques rely on restoration rather than optimization of flow into the atretic arteries. An improved understanding of cellular response post anastomosis may result in reduced restenosis. Here, an in vitro platform is used to model anastomosis in pulmonary arteries (PAs) and for procedural planning to reduce vascular restenosis. Bifurcated PAs are bioprinted within 3D hydrogel constructs to simulate a reestablished intervascular connection. The PA models are seeded with human endothelial cells and perfused at physiological flow rate to form endothelium. Particle image velocimetry and computational fluid dynamics modeling show close agreement in quantifying flow velocity and wall shear stress within the bioprinted arteries. These data are used to identify regions with greatest levels of shear stress alterations, prone to stenosis. Vascular geometry and flow hemodynamics significantly affect endothelial cell viability, proliferation, alignment, microcapillary formation, and metabolic bioprofiles. These integrated in vitro-in silico methods establish a unique platform to study complex cardiovascular diseases and can lead to direct clinical improvements in surgical planning for diseases of disturbed flow.
STIMULANT EFFECTS OF A SULFONAMIDE PREPARATION, SULFAPHENAZOLE, ON THE CENTRAL NERVOUS SYSTEM IN RATS.
Authors: W B RICE, M G ALLMARK
Journal: Canadian Medical Association journal (1965)

Sulfaphenazole (Orisul), which had been reported to cause a convulsant syndrome in young European children, lowered the electroshock threshold in rats when administered in the form of tablets or suspension. This effect was not obtained with a sample of sulfaphenazole pure drug or with several other long-acting oral sulfonamide preparations, but was obtained with a mixture of impurities which had been found in the same lot of Orisul that had reportedly caused the convulsant syndrome. A change in the method of manufacture now provides a product which is free from these impurities.
Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis
Authors: Han Wang, Hongji Zhang, Yu Wang, Zachary J. Brown, Yujia Xia, Zheng Huang, Chengli Shen, Zhiwei Hu, Joal Beane, Ephraim A. Ansa-Addo, Hai Huang, Dean Tian, Allan Tsung
Journal: Journal of Hepatology (2021)
健常被験者におけるヒト好酸球のin vivo動態を確立するための111-インジウム標識自己好酸球の使用
Authors: Farahi Neda, R Singh Nanak, Heard Sarah, Loutsios Chrystalla, Summers Charlotte, K Solanki Chandra, Solanki Kishor, K Balan Kottekkattu, Ruparelia Prina, Peters A. Michael, M Condliffe Alison, R Chilvers Edwin
Journal: Blood (2012)
O-9 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial
Authors: M. Ducreux, J. Tabernero, A. Grothey, D. Arnold, P. O'Dwyer, M. Perdicchio, Z. Assaf, M. Das Thakur, N. Irahara, A. Tahiri, H. Schmoll, E. Van Cutsem, A. de Gramont
Journal: Annals of Oncology (2021)
Transgenic expression of heparin-binding EGF-like growth factor in the mice liver accelerates the hepatocytes proliferation after partial hepatectomy.
Authors: Miyagawa J, Saito M, Higashiyama S, Taniguchi N, Matsuzawa Y, Yamada A, Ito N, Umeki S, Inui Y, Tamura S, Kohno K, Kawata S, Kiso S
Journal: Hepatology (1998)
Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas
Authors: Kosuke Aoki, Hiromichi Suzuki, Takashi Yamamoto, Kimiyo N. Yamamoto, Sachi Maeda, Yusuke Okuno, Melissa Ranjit, Kazuya Motomura, Fumiharu Ohka, Kuniaki Tanahashi, Masaki Hirano, Tomohide Nishikawa, Hiroyuki Shimizu, Yotaro Kitano, Junya Yamaguchi, Shintaro Yamazaki, Hideo Nakamura, Masamichi Takahashi, Yoshitaka Narita, Mitsutoshi Nakada, Shoichi Deguchi, Masahiro Mizoguchi, Yasutomo Momii, Yoshihiro Muragaki, Tatsuya Abe, Jiro Akimoto, Toshihiko Wakabayashi, Ryuta Saito, Seishi Ogawa, Hiroshi Haeno, Atsushi Natsume
Journal: Cancer Research (2021)

Abstract Isocitrate dehydrogenase-mutant low-grade gliomas (IDHmut-LGG) grow slowly but frequently undergo malignant transformation, which eventually leads to premature death. Chemotherapy and radiotherapy treatments prolong survival, but can also induce genetic (or epigenetic) alterations involved in transformation. Here, we developed a mathematical model of tumor progression based on serial tumor volume data and treatment history of 276 IDHmut-LGGs classified by chromosome 1p/19q codeletion (IDHmut/1p19qcodel and IDHmut/1p19qnoncodel) and performed genome-wide mutational analyses, including targeted sequencing and longitudinal whole-exome sequencing data. These analyses showed that tumor mutational burden correlated positively with malignant transformation rate, and chemotherapy and radiotherapy significantly suppressed tumor growth but increased malignant transformation rate per cell by 1.8 to 2.8 times compared with before treatment. This model revealed that prompt adjuvant chemoradiotherapy prolonged malignant transformation-free survival in small IDHmut-LGGs (≤ 50 cm3). Furthermore, optimal treatment differed according to genetic alterations for large IDHmut-LGGs (&amp;gt; 50 cm3); adjuvant therapies delayed malignant transformation in IDHmut/1p19qnoncodel but often accelerated it in IDHmut/1p19qcodel. Notably, PI3K mutation was not associated with malignant transformation but increased net postoperative proliferation rate and decreased malignant transformation-free survival, prompting the need for adjuvant therapy in IDHmut/1p19qcodel. Overall, this model uncovered therapeutic strategies that could prevent malignant transformation and, consequently, improve overall survival in patients with IDHmut-LGGs. Significance: A mathematical model successfully estimates malignant transformation-free survival and reveals a link between genetic alterations and progression, identifying precision medicine approaches for optimal treatment of IDH-mutant low-grade gliomas.
Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders
Authors: Rebecca A. Marsh, Kyle Hebert, Soyoung Kim, Christopher C. Dvorak, Victor M. Aquino, K. Scott Baker, Deepak Chellapandian, Blachy Dávila Saldaña, Christine N. Duncan, Michael J. Eckrich, George E. Georges, Timothy S. Olson, Michael A. Pulsipher, Shalini Shenoy, Elizabeth Stenger, Mark Vander Lugt, Lolie C. Yu, Andrew R. Gennery, Mary Eapen
Journal: Journal of Allergy and Clinical Immunology (2021)
P-224 Expression of major components of the exosome biogenesis pathway is deregulated in colorectal cancer and associated with clinical outcome: Preliminary results from an association study
Authors: A. Kottorou, F. Dimitrakopoulos, A. Antonacopoulou, T. Makatsoris, M. Stavropoulos, A. Koutras, H. Kalofonos
Journal: Annals of Oncology (2021)
With or without ROSE: does fine-needle biopsy settle the debate on rapid on-site evaluation?
Authors: Marcin Polkowski
Journal: Endoscopy (2021)

Rapid onsite evaluation (ROSE) involves an assessment of samples obtained by fine-needle aspiration (FNA) for adequacy and preliminary diagnosis that is performed by a cytopathologist or cytotechnician attending the procedure. Originally used to optimize the yield of percutaneous FNA, ROSE was quickly adopted for endoscopic ultrasound (EUS)-guided FNA soon after the technique became available. A debate has ensued on whether ROSE improves the results of EUS-FNA and, if so, whether its advantages are worth the effort and cost of organizing the service. More than two decades later the debate continues.
PHASE II TRIAL OF COMBINED CHEMOTHERAPY WITH IRINOTECAN, S-1, AND BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Authors: Asaka M, Sakata Y, Munakata M, Kudo M, Miyagishima T, Hatanaka K, Nakamura M, Sogabe S, Yuki S, Komatsu Y
Journal: Annals of Oncology (2010)
P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
Authors: J. Tabernero, D. Cohen, E. Van Cutsem, Y. Janjigian, Y. Bang, S. Qin, A. Wang, N. Hawk, C. Shih, P. Bhagia, K. Shitara
Journal: Annals of Oncology (2021)
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
Authors: Quy Le, Sommer Castro, Thao Tang, Anisha M. Loeb, Tiffany Hylkema, Cyd Nourigat McKay, LaKeisha Perkins, Shivani Srivastava, Lindsey Call, Jenny Smith, Amanda Leonti, Rhonda Ries, Laura Pardo, Michael R. Loken, Colin Correnti, Salvatore Fiorenza, Cameron J. Turtle, Stanley Riddell, Katherine Tarlock, Soheil Meshinchi
Journal: Clinical Cancer Research (2021)

Abstract Purpose: We previously identified mesothelin (MSLN) as highly expressed in a significant fraction of acute myeloid leukemia (AML) but entirely silent in normal hematopoiesis, providing a promising antigen for immunotherapeutic targeting that avoids hematopoietic toxicity. Given that T cells genetically modified to express chimeric antigen receptors (CAR) are effective at eradicating relapsed/refractory acute lymphocytic leukemia, we developed MSLN-directed CAR T cells for preclinical evaluation in AML. Experimental Design: The variable light (VL) and heavy (VH) sequences from the MSLN-targeting SS1P immunotoxin were used to construct the single-chain variable fragment of the standard CAR containing 41-BB costimulatory and CD3Zeta stimulatory domains. The preclinical efficacy of MSLN CAR T cells was evaluated against AML cell lines and patient samples expressing various levels of MSLN in vitro and in vivo. Results: We demonstrate that MSLN is expressed on the cell surface of AML blasts and leukemic stem cell–enriched CD34+CD38− subset, but not on normal hematopoietic stem and progenitor cells (HSPC). We further establish that MSLN CAR T cells are highly effective in eliminating MSLN-positive AML cells in cell line– and patient-derived xenograft models. Importantly, MSLN CAR T cells can target and eradicate CD34+CD38− cells without impacting the viability of normal HSPCs. Finally, we show that CAR T-cell functionality can be improved by inhibition of the ADAM17 metalloprotease that promotes shedding of MSLN. Conclusions: These findings demonstrate that MSLN is a viable target for CAR T-cell therapy in AML and that inhibiting MSLN shedding is a promising approach to improve CAR T-cell efficacy.
34週未満妊娠で生まれた早産児の年齢の4対6カ月時点での相補的摂食:無作為化,非盲検,多施設試験【Powered by NICT】
Authors: Gupta Shuchita, Agarwal Ramesh, Aggarwal Kailash Chandra, Chellani Harish, Duggal Anil, Arya Sugandha, Bhatia Sunita, Sankar Mari Jeeva, Sreenivas Vishnubhatla, Jain Vandana, Gupta Arun Kumar, Deorari Ashok K, Paul Vinod K
Journal: The Lancet Global Health (2017)
Methylation changes in early embryonic genes in cancer
Authors: Tony W. Li, Peter A. Jones
Journal: Cancer Research (2006)

30  One theory for carcinogenesis is that it may be the result of ectopic activation of an embryonic gene expression program in somatic cells. Gene expression during embryogenesis is dynamic and is tightly coordinated both temporally and spatially within the developing embryo. Early embryonic genes are expressed in early undifferentiated embryonic stem cells, down-regulated at the onset of differentiation and generally absent in adult somatic tissues. Some of these genes have been shown to be over-expressed in a variety of cancers. The mechanism(s) that control the dynamic expression of these early embryonic genes is not fully elucidated. One potential mechanism that may play a role in the expression of these genes is DNA methylation, a well known epigenetic modification. Active and passive demethylation occurs in the early zygote which is followed by the re-establishment of DNA methylation patterns on the genome. However, the role of DNA methylation in the regulation of embryonic gene expression is poorly understood. One could then hypothesize that de-novo methylation of early embryonic genes occurs to permanently silence its expression in adult somatic tissue. Therefore, we analyzed the methylation status of the promoter region of nine early embryonic genes by Ms-SNuPE and bisulfite genomic sequencing in adult somatic tissues. The early embryonic genes FOXD3, SOX2, UTF1, and ZFP42 are CpG rich with low levels of DNA methylation in all somatic tissues tested while GDF3 is highly methylated in sperm and white blood cells but low to moderate in the rest of the somatic tissues. These results suggest that de-novo methylation does not occur in the permanent silencing of these genes. In contrast, NANOG, POU5F1 (Oct-4), STELLAR, and TDGF1 (Cripto-1) are moderately to highly methylated in almost all somatic tissues, including sperm. The high level of methylation corresponds with the general lack of expression detected by RT-PCR in the same somatic tissues tested. This suggests DNA methylation may play a specific role in the control of a subset of embryonic gene expression and perhaps in cancers where these genes are aberrantly expressed.
Association of entirely claims-based frailty indices with long-term outcomes in patients with acute myocardial infarction, heart failure, or pneumonia: a nationwide cohort study in Turkey
Authors: Harun Kundi, Nazim Coskun, Metin Yesiltepe
Journal: The Lancet Regional Health - Europe (2021)

Several countries have increasingly focused on improving care for acute myocardial infarction (AMI), heart failure (HF), and pneumonia to reduce their readmissions and mortality rates. Frailty is becoming increasingly important to accurately predict healthcare utilization for the aging population. The preferred method for the measurement of frailty remains unclear, and current risk-adjustment models do not account for frailty. We sought to compare commonly used frailty indices in terms of the ability to predict clinical adverse outcomes in AMI, HF, and pneumonia patients.A nationwide cohort study included AMI, HF, and pneumonia with 65 years and older patients in the Turkey between January 1 and December 31, 2018. The primary predictor of interest was frailty. We used two claims-based frailty indices (Johns Hopkins Claims-Based Frailty Index and Hospital Frailty Risk Score) to assess frailty. The main outcome was all-cause long-term mortality up to 3 years. Time to death was calculated as the time period between the date of first admission and the date of death. Patients were censored as of September 30, 2020, which marked the end of the follow-up period.Of the 200,948 patients, 35,096 (17.5%) had AMI, 62,403 (31.1%) had HF, and 103,449 (51.5%) had pneumonia. Johns Hopkins Claims-Based Frailty Index (c-statistics for long-term mortality: 0.68 in AMI, 0.61 in HF, 0.64 in pneumonia) was better compared to Hospital Frailty Risk Score (c-statistics for long-term mortality: AMI=0.62, HF=0.58, pneumonia=0.62) (DeLong p<0.001 in all).Readmission and mortality rates after AMI, HF, and pneumonia gradually increases with increasing frailty score. While the Hospital Frailty Risk Score had a better discrimination for predicting readmissions, Johns Hopkins Claims-Based Frailty Index had a better discrimination for predicting mortality. These findings should be taken into account for a better evaluation of hospital performance.This study was supported by funding from The Scientific and Technological Research Council of Turkey (grant 120S422, HK).
Head and Neck Cancers Clinical Practice Guidelines in Oncology
Authors: Arlene A Forastiere, Kian Ang, David Brizel, Bruce Earl Brockstein, Frank Dunphy, David W Eisele, Helmuth Goepfert, Wesley L Hicks, Merrill S Kies, William M Lydiatt, Ellie Maghami, Thomas McCaffrey, Bharat B Mittal, David G Pfister, Harlan A Pinto, Marshall R Posner, John A Ridge, Sandeep Samant, David E Schuller, Jatin P Shah, Sharon Spencer, Andrew Trotti, Richard H Wheeler, Gregory T Wolf, Frank Worden, Bevan Yueh
Journal: Journal of the National Comprehensive Cancer Network (2005)

The NCCN Head and Neck Cancers guidelines address tumors arising in the lip, oral cavity, oropharynx, hypopharynx, glottic and supraglottic larynx, paranasal (ethmoid and maxillary) sinuses, nasopharynx, and salivary glands, as well as occult primary cancer. Approximately 39,250 new cases of oral cavity, pharyngeal, and laryngeal cancers will occur in 2005, which accounts for about 3% of new cancer cases in the United States. An estimated 11,090 deaths from head and neck (H&amp;N) cancers will occur in 2005. Alcohol and tobacco abuse are common etiologic factors in cancers of the oral cavity, oropharynx, hypopharynx, and larynx. Moreover, because the entire aerodigestive tract epithelium may be exposed to these carcinogens, patients with H&amp;N cancer are at risk for developing second primary neoplasms of the H&amp;N, lung, and esophagus. For the most recent version of the guidelines, please visit NCCN.org
Allergen databases
Authors: V. Brusic, M. Millot, N. Petrovsky, S. M. Gendel, O. Gigonzac, S. J. Stelman
Journal: Allergy (2003)

Allergies represent a significant medical and industrial problem. Molecular and clinical data on allergens are growing exponentially and in this article we have reviewed nine specialized allergen databases and identified data sources related to protein allergens contained in general purpose molecular databases. An analysis of allergens contained in public databases indicates a high level of redundancy of entries and a relatively low coverage of allergens by individual databases. From this analysis we identify current database needs for allergy research and, in particular, highlight the need for a centralized reference allergen database.
Broadly neutralizing antibody–derived CAR T cells reduce viral reservoir in individuals infected with HIV-1
Authors: Bingfeng Liu, Wanying Zhang, Baijin Xia, Shuliang Jing, Yingying Du, Fan Zou, Rong Li, Lijuan Lu, Shaozhen Chen, Yonghong Li, Qifei Hu, Yingtong Lin, Yiwen Zhang, Zhangping He, Xu Zhang, Xiejie Chen, Tao Peng, Xiaoping Tang, Weiping Cai, Ting Pan, Linghua Li, Hui Zhang
Journal: Journal of Clinical Investigation (2021)

BACKGROUND. Chimeric antigen receptor (CAR) T cells have emerged as an approach to treat malignant tumors. This strategy has also been proposed for the treatment of HIV-1 infection. We have developed a broadly neutralizing antibody–derived (bNAb-derived) CAR T cell therapy that can exert specific cytotoxic activity against HIV-1–infected cells.
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
Authors: Tien Dam, Adam L. Boxer, Lawrence I. Golbe, Günter U. Höglinger, Huw R. Morris, Irene Litvan, Anthony E. Lang, Jean-Christophe Corvol, Ikuko Aiba, Michael Grundman, Lili Yang, Beth Tidemann-Miller, Joseph Kupferman, Kristine Harper, Kubra Kamisoglu, Michael J. Wald, Danielle L. Graham, Liz Gedney, John O’Gorman, Samantha Budd Haeberlein
Journal: Nature Medicine (2021)
Oral frailty and its determinants in older age: a systematic review
Authors: Vittorio Dibello, Roberta Zupo, Rodolfo Sardone, Madia Lozupone, Fabio Castellana, Antonio Dibello, Antonio Daniele, Giovanni De Pergola, Ilaria Bortone, Luisa Lampignano, Gianluigi Giannelli, Francesco Panza
Journal: The Lancet Healthy Longevity (2021)
Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis
Authors: Zara Izadi, Jing Li, Michael Evans, Nevin Hammam, Patricia Katz, Alexis Ogdie, Lisa G. Suter, Jinoos Yazdany, Gabriela Schmajuk
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Little is known about the association of poverty with functional status (FS) in patients with rheumatoid arthritis (RA) who use rheumatology care. <h3>Objectives</h3> To examine the association between socioeconomic status (SES) and FS among patients with RA and to evaluate the association between SES and functional declines over time in patients who received at least some rheumatology care. <h3>Design, Setting, and Participants</h3> This cohort study used data from the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) registry between January 1, 2016, and December 31, 2018. Analyses included all adult patients with a confirmed RA diagnosis (ie, had ≥2 encounters associated with RA<i>International Classification of Diseases </i>codes ≥30 days apart) and at least 1 FS score documented between 2016 and 2018 seen at participating rheumatology practices. Data analysis was conducted from April to December 2020. <h3>Exposures</h3> The Area Deprivation Index (ADI), a zip code–based indicator of neighborhood poverty, was used as a proxy for SES. ADI scores were categorized into quintiles. <h3>Main Outcomes and Measures</h3> FS measures included Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire Disability index, and Health Assessment Questionnaire–II. Cross-sectionally, mean FS scores were compared across ADI quintiles. Longitudinally, among patients with at least 2 FS scores, multilevel multivariate regression computed the probability of functional decline, defined as a change greater than the minimum clinically important difference, across ADI quintiles. In a subgroup analysis, whether disease activity mediated the association between SES and functional decline was examined. <h3>Results</h3> Of the 83 965 patients included in the study, 66 649 (77%) were women, and 60 037 (72%) were non-Hispanic White. Mean (SD) age was 63.4 (13.7) years. MDHAQ was the most reported FS measure (56 928 patients [67.8%]). For all measures, mean (SD) FS score was worse at lower SES levels (eg, for MDHAQ quintile 1: 1.79 [1.87]; quintile 5: 2.43 [2.17]). In longitudinal analyses, the probability of functional decline was 14.1% (95% CI, 12.5%-15.7%) in the highest SES quintile and 18.9% (95% CI, 17.1%-20.7%) in the lowest SES quintile. The association between SES and functional decline was partially mediated (7%; 95% CI, 4%-22%) by disease activity. <h3>Conclusions and Relevance</h3> In this cohort study of patients with RA, worse FS and faster declines in functioning over time were observed in patients with lower SES. These findings provide a framework for monitoring disparities in RA and for generating evidence to spur action toward achieving health equity.